Liver Transplant

Transplant Programs

Raising the Standard

Led by a nationally acclaimed surgeon, our Liver Transplant Program elevates the quality of care available locally

Leading by experience

Saint Luke’s Health System performed the first ever liver transplant in Kansas City in 1980. We were just the third hospital in the U.S. to perform the procedure. Having performed more than 1,000 transplants, our surgical team is the most experienced in the area.

Saint Luke’s also offers some of the shortest liver transplant wait times in the country. In fact, our average time to transplant is below that of the Midwest Transplant Network’s average time to transplant.

Transplant program, Median time to transplant in months*

  • Saint Luke’s Hospital of Kansas City: 4.6 months
  • University of Kansas Hospital: 6.2 months
  • Barnes-Jewish Hospital (St. Louis): 6.2 months
  • The Nebraska Medical Center: 7.4 months

Patient-focused care

At Saint Luke’s, we rely on collaboration across specialists in many disciplines to find the best treatment for you. You will have a hepatologist dedicated to helping you manage your liver disease all the way from diagnosis to transplant. The liver transplant team is here to provide you and your loved ones with the best care throughout the transplantation process.

Our multidisciplinary team of specialists provides patients with treatment options backed by the latest research and years of clinical expertise. We also ensure every patient has easy access to transplant resources and services, including convenient appointment scheduling. In addition, multiple testing sites allow pre-transplant evaluation testing to be done close to home.

We treat such common conditions as:

  • Cirrhosis
  • Chronic hepatitis
  • Metabolic liver disease
  • Liver tumors

Current clinical trials

Clinical trials help physicians and researchers find better ways to prevent, diagnose, and treat liver disease. For many patients, participation in a clinical trial improves outcomes and quality of life. Ongoing liver disease clinical trials include:

  • RESOLVE IT: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis
  • STELLAR 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
  • STELLAR 4: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
  • HBV-02-013: Multi-Center, Prospective Evaluation of the Beckman Coulter DxN HBV Viral Load Assay as an Aid in the Management of HBV-infected Individuals Undergoing Antiviral Therapy
  • Protocol: Impact of Genetic Factors on the Outcomes of Hepatitis C Cirrhosis after Viral Treatment
  • Protocol: Liver Center Tissue Procurement and Banking Protocol
  • 16HEP01: Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for Use in the Development of a Liver Fibrosis Test

For more information about current liver disease clinical trials at Saint Luke's, call 816-932-4655.

* Information from Scientific Registry of Transplant Recipients (SRTR)